MPL Adjuvant Contains Competitive Antagonists of Human TLR4
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.577823
Abstract: Monophosphoryl lipid A (MPL®) is the first non-alum vaccine adjuvant to achieve widespread clinical and market acceptance, a remarkable achievement given that it is manufactured from a Salmonella enterica endotoxin. To understand how MPL® successfully… read more here.
Keywords: human tlr4; antagonists human; mpl; mpl adjuvant ... See more keywords